Recommendations for risk categorization and prophylaxis of invasive fungal diseases in hematological malignancies: A critical review of evidence and expert opinion (TEO-4)
dc.contributor.author | Boğa, Can | |
dc.contributor.author | Bolaman, Zahit | |
dc.contributor.author | Çağırgan, Seçkin | |
dc.contributor.author | Karadoğan, İhsan | |
dc.contributor.author | Özcan, Mehmet Ali | |
dc.contributor.author | Saba, Rabin | |
dc.contributor.author | Sönmez, Mehmet | |
dc.contributor.author | Şenol, Esin | |
dc.contributor.author | Akan, Hamdi | |
dc.contributor.author | Akova, Murat | |
dc.contributor.buuauthor | Özkalemkaş, Fahir | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAG-8495-2021 | tr_TR |
dc.contributor.scopusid | 6601912387 | tr_TR |
dc.date.accessioned | 2024-02-19T12:38:38Z | |
dc.date.available | 2024-02-19T12:38:38Z | |
dc.date.issued | 2015 | |
dc.description.abstract | This is the last of a series of articles on invasive fungal infections prepared by opinion leaders in Turkey. The aim of these articles is to guide clinicians in managing invasive fungal diseases in hematological malignancies and stem cell transplantation based on the available best evidence in this field. The previous articles summarized the diagnosis and treatment of invasive fungal disease and this article aims to explain the risk categorization and guide the antifungal prophylaxis in invasive fungal disease. | en_US |
dc.identifier.citation | Boğa, C. vd. (2015). "Recommendations for risk categorization and prophylaxis of invasive fungal diseases in hematological malignancies: A critical review of evidence and expert opinion (TEO-4)". Turkish Journal of Hematology, 32(2), 100-117. | en_US |
dc.identifier.endpage | 117 | tr_TR |
dc.identifier.issn | 1300-7777 | |
dc.identifier.issue | 2 | tr_TR |
dc.identifier.pubmed | 26316478 | tr_TR |
dc.identifier.scopus | 2-s2.0-84930743919 | tr_TR |
dc.identifier.startpage | 100 | tr_TR |
dc.identifier.uri | https://doi.org/10.4274/tjh.2014.0277 | en_US |
dc.identifier.uri | https://jag.journalagent.com/tjh/pdfs/TJH_32_2_100_117.pdf | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39853 | en_US |
dc.identifier.volume | 32 | tr_TR |
dc.identifier.wos | 000369116200001 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.trdizin | TrDizin | tr_TR |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Galenos Yayınları | |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Turkish Journal of Hematology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Hematology | en_US |
dc.subject | Hematological malignancy | en_US |
dc.subject | Invasive fungal infections | en_US |
dc.subject | Prophylaxis | en_US |
dc.subject | Risk | en_US |
dc.subject | Stem-cell transplantation | en_US |
dc.subject | Receiving antifungal prophylaxis | en_US |
dc.subject | Bone-marrow-transplantation | en_US |
dc.subject | Placebo-controlled trial | en_US |
dc.subject | Double-blind trial | en_US |
dc.subject | Cancer-patients | en_US |
dc.subject | Mold infections | en_US |
dc.subject | Single-center | en_US |
dc.subject | Pulmonary aspergillosis | en_US |
dc.subject | Fluconazole prophylaxis | en_US |
dc.subject.emtree | Alemtuzumab | en_US |
dc.subject.emtree | Amphotericin B deoxycholate | en_US |
dc.subject.emtree | Amphotericin B lipid complex | en_US |
dc.subject.emtree | Anidulafungin | en_US |
dc.subject.emtree | Anthracycline | en_US |
dc.subject.emtree | Caspofungin | en_US |
dc.subject.emtree | Cell surface protein | en_US |
dc.subject.emtree | Corticosteroid | en_US |
dc.subject.emtree | Cytochrome P450 isoenzyme | en_US |
dc.subject.emtree | Diphtheria toxoid CRM197 | en_US |
dc.subject.emtree | Echinocandin | en_US |
dc.subject.emtree | Fluconazole | en_US |
dc.subject.emtree | Fructose bisphosphate aldolase | en_US |
dc.subject.emtree | Glucan glucosidase | en_US |
dc.subject.emtree | Glucuronoxylomannan | en_US |
dc.subject.emtree | Itraconazole | en_US |
dc.subject.emtree | Laminaran | en_US |
dc.subject.emtree | Malate dehydrogenase | en_US |
dc.subject.emtree | Mannan | en_US |
dc.subject.emtree | Micafungin | en_US |
dc.subject.emtree | Placebo | en_US |
dc.subject.emtree | Posaconazole | en_US |
dc.subject.emtree | Rapamycin | en_US |
dc.subject.emtree | Recombinant protein | en_US |
dc.subject.emtree | Rituximab | en_US |
dc.subject.emtree | Signaling lymphocyte activation molecule associated protein | en_US |
dc.subject.emtree | Triazole | en_US |
dc.subject.emtree | Unindexed drug | en_US |
dc.subject.emtree | Vincristine | en_US |
dc.subject.emtree | Voriconazole | en_US |
dc.subject.emtree | Antifungal agent | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Immunosuppressive agent | en_US |
dc.subject.emtree | Acute myeloblastic leukemia | en_US |
dc.subject.emtree | Allogeneic stem cell transplantation | en_US |
dc.subject.emtree | Cryptococcosis | en_US |
dc.subject.emtree | Disease association | en_US |
dc.subject.emtree | Drug monitoring | en_US |
dc.subject.emtree | Graft versus host reaction | en_US |
dc.subject.emtree | Hematologic malignancy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Infection risk | en_US |
dc.subject.emtree | Invasive aspergillosis | en_US |
dc.subject.emtree | Invasive candidiasis | en_US |
dc.subject.emtree | Mass spectrometry | en_US |
dc.subject.emtree | Meta analysis (topic) | en_US |
dc.subject.emtree | Mycosis | en_US |
dc.subject.emtree | Myelodysplastic syndrome | en_US |
dc.subject.emtree | Randomized controlled trial (topic) | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Risk assessment | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Adverse effects | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Chemically induced | en_US |
dc.subject.emtree | Complication | en_US |
dc.subject.emtree | Cross infection | en_US |
dc.subject.emtree | Disinfection | en_US |
dc.subject.emtree | Febrile neutropenia | en_US |
dc.subject.emtree | Hematologic neoplasms | en_US |
dc.subject.emtree | Immunocompromised patient | en_US |
dc.subject.emtree | Invasive fungal infections | en_US |
dc.subject.emtree | Opportunistic infections | en_US |
dc.subject.emtree | Practice guideline | en_US |
dc.subject.emtree | Procedures | en_US |
dc.subject.emtree | Secondary prevention | en_US |
dc.subject.emtree | Transplantation conditioning | en_US |
dc.subject.mesh | Antifungal agents | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Cross infection | en_US |
dc.subject.mesh | Disinfection | en_US |
dc.subject.mesh | Febrile neutropenia | en_US |
dc.subject.mesh | Hematologic neoplasms | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunocompromised host | en_US |
dc.subject.mesh | Immunosuppressive agents | en_US |
dc.subject.mesh | Invasive fungal infections | en_US |
dc.subject.mesh | Opportunistic infections | en_US |
dc.subject.mesh | Practice guidelines as topic | en_US |
dc.subject.mesh | Risk assessment | en_US |
dc.subject.mesh | Secondary prevention | en_US |
dc.subject.mesh | Transplantation conditioning | en_US |
dc.subject.scopus | Antifungal agents; Posaconazole; Micafungin | en_US |
dc.subject.wos | Hematology | en_US |
dc.title | Recommendations for risk categorization and prophylaxis of invasive fungal diseases in hematological malignancies: A critical review of evidence and expert opinion (TEO-4) | en_US |
dc.title.alternative | Hematolojik malignitelerdeki invazif fungal enfeksiyon riskinin belirlenmesi ve profilaksi: Kanıtlara eleştirel bakış ve Türk uzman görüşleri (TUG-4) | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q4 | en_US |